Avigen Inc. - AVGN- Profile

Avigen, Inc.. The Group's principal activity is to develop and commercialize small molecule therapeutics and biologics to treat serious neurological and neuromuscular disorders. The Group product candidates primarily address neuromuscular spasm and spasticity and neuropathic pain. The products in development are AV650 for Neuromuscular spasm and spasticity, AV411 for Neuropathic pain and other neurological disorders, AV513 for Bleeding disorders, including hemophilia. In January 2006, the Group acquired exclusive license rights to develop and commercialize proprietary formulations of the compound tolperisone, which named AV650, for the North American market. These rights include relevant patent filings, as well as clinical data held by SDI Diagnostics International LTD, a division of Sanochemia Pharmazeutika AG, or Sanochemia relating to AV650. Develops and commercializes small molecule therapeutics and biologics to treat serious neurological and neuromuscular disorders